Adrenomed AG

https://www.adrenomed.com

Adrenomed AG is a privately financed biopharmaceutical company, based in Hennigsdorf near Berlin, Germany, with a clear mission to improve survival by improving vascular integrity in critically ill patients. Its lead candidate, Adrecizumab, a monoclonal antibody therapy targeting the vasoactive Adrenomedullin system, is in clinical testing for septic shock. Impaired vascular integrity is a pathology that serves a variety of medical conditions. A further indication besides sepsis is acute decompensated heart failure. About Adrenomedullin and Adrecizumab Adrenomedullin is a strong vasodilatory hormone released by endothelial cells. It is a key regulator of blood pressure and vascular tone and plays a pivotal role in the development of septic shock. Adrecizumab is a proprietary humanized monoclonal Adrenomedullin-specific antibody, as first-in-class therapy for the treatment and prevention of impaired vascular integrity, which is a hallmark of septic shock. Adrecizumab showed excellent safety & tolerability as well as high efficacy in a variety of preclinical animal models, mimicking human standard of care treatment on ICU. In several resuscitated vascular integrity models (mouse, rat, pig), Adrecizumab reduced vascular leakage, stabilized the circulation, by restoring blood pressure, normalized fluid balance and reduced vasopressor demand, improved renal function and reduced mortality from septic shock by 50%. The excellent tolerability and safety of Adrecizumab was confirmed in clinical Phase-I studies in healthy subjects with and without LPS challenge. *

	Start	2010-10-20 established
	Industry	adrecizumab
	Industry 2	drug development
	Person	Baiker, Wolfgang (Adrenomed 202101– CEO + Venture Partner at Wellington Partners before Boehringer Ingelheim)
	Person 2	Bergmann, Andreas (Sphingotec GmbH 201301 Managing Director)

	Region	Hennigsdorf
	Country	Germany
	Street	15a Neuendorfstr.
	City	16761 Hennigsdorf
	Tel	+49-3302-207780
		Address record changed: 2020-12-11

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Adrenomed AG. (12/11/17). "Press Release: Adrenomed AG Doses First Patient in Proof of Concept Study with Adrecizumab to Treat Patients with Early Septic Shock". Hennigsdorf.

		Record changed: 2021-01-13